Literature DB >> 17476103

Current status of surgery for pancreatic cancer.

Koichi Hirata1, Shinichi Egawa, Yasutoshi Kimura, Takayuki Nobuoka, Hidenori Oshima, Tadashi Katsuramaki, Toru Mizuguchi, Tomohisa Furuhata.   

Abstract

BACKGROUND: In Japan the annual incidence of pancreatic cancer has increased over the last decade, but no advancement has been made in the long-term prognosis after resection. The significant differences in the surgical procedures between Western countries and Japan have been discussed. Therefore, an adequate comparison and analysis of the data from Japan, Europe and the USA is required. This review evaluates many important published reports from Japan which influence surgical procedure.
METHODS: Several important highlights and controversies regarding the concept of surgical treatment and surgical procedure are discussed comparing the results in Japan with those in Western countries.
RESULTS: No significant difference in diagnostic strategy using various imaging methods was observed between Japan and Europe. The stage classification for pancreatic cancer by the Japanese Pancreatic Society (JPS) seems to be superior to others, because the results on long-term prognosis after pancreatectomy of cases with pancreatic head cancer, diagnosed as tubular adenocarcinoma, has been arranged logically. Pancreatectomy with extended radical dissection is recommended in Japan, but several clinical studies from Europe and the USA suggest that this is ineffective. The basic concepts of this controversy have recently come closer altogether. Scientific clinical trials for instance on the necessity of adjuvant treatment, etc., are now on-going.
CONCLUSION: The characteristics on diagnosis and treatment of pancreatic cancer in Japan are described. The JPS registration system for pancreatic cancer can provide much more information, i.e. dependency on diagnostic methods, highly frequent sites of lymph node and of distant metastases, the prognosis of small pancreatic cancers, etc. The indication for any surgical treatments should be limited to cases with the possibility of cancer free margins. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17476103     DOI: 10.1159/000102067

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  20 in total

1.  Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

Authors:  Hayato Fujita; Kenoki Ohuchida; Kazuhiro Mizumoto; Soichi Itaba; Tetsuhide Ito; Kohei Nakata; Jun Yu; Tadashi Kayashima; Ryota Souzaki; Tatsuro Tajiri; Tatsuya Manabe; Takao Ohtsuka; Masao Tanaka
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Effectiveness of endoscopic self-expandable metal stent placement for afferent loop obstruction caused by pancreatic cancer recurrence after pancreaticoduodenectomy.

Authors:  Arata Sakai; Hideyuki Shiomi; Yoshihiro Okabe; Yousuke Yagi; Takashi Kobayashi; Yuuki Shiomi; Mamoru Takenaka; Namiko Hoshi; Yoshifumi Arisaka; Hiromu Kutsumi; Takeshi Azuma
Journal:  Clin J Gastroenterol       Date:  2015-02-24

3.  The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-β1, CA199, and CEA.

Authors:  Gang Zhou; David Chiu; Dajiang Qin; Lizhi Niu; Jinlei Cai; Lihua He; Wenhao Huang; Kecheng Xu
Journal:  Mol Biotechnol       Date:  2012-09       Impact factor: 2.695

4.  Negative methylation status of vimentin predicts improved prognosis in pancreatic carcinoma.

Authors:  Yi-Feng Zhou; Wei Xu; Xia Wang; Jin-Shan Sun; Jing-Jing Xiang; Zhao-Shen Li; Xiao-Feng Zhang
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer.

Authors:  Jian-Yu Yang; Yong-Wei Sun; De-Jun Liu; Jun-Feng Zhang; Jiao Li; Rong Hua
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

6.  microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy.

Authors:  Jie Xiao; Feng Peng; Chao Yu; Min Wang; Xu Li; Zhipeng Li; Jianxin Jiang; Chengyi Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

7.  MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.

Authors:  Chao Ma; Tao Huang; Yue-Chao Ding; Wei Yu; Qian Wang; Bo Meng; Su-Xia Luo
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

8.  Mass-forming pancreatitis with positive fluoro-2-deoxy-D: -glucose positron emission tomography and positive diffusion-weighted imaging-magnetic resonance imaging: Report of a case.

Authors:  Masaaki Nishi; Toru Ikegami; Satoru Imura; Yuji Morine; Hirofumi Kanemura; Hiroki Mori; Yusuke Arakawa; Jun Hanaoka; Koji Sugimoto; Mitsuo Shimada
Journal:  Surg Today       Date:  2009-02-07       Impact factor: 2.549

9.  MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3.

Authors:  Zhipeng Li; Xu Li; Chao Yu; Min Wang; Feng Peng; Jie Xiao; Rui Tian; Jianxin Jiang; Chengyi Sun
Journal:  Tumour Biol       Date:  2014-10-26

10.  Downregulation of CPE regulates cell proliferation and chemosensitivity in pancreatic cancer.

Authors:  Anan Liu; Chenghao Shao; Gang Jin; Rui Liu; Jun Hao; Zhuo Shao; Quyang Liu; Xiangui Hu
Journal:  Tumour Biol       Date:  2014-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.